Cannasat Therapeutics and IntelGenx Enter into a Collaborative Agreement to Develop Novel Drug Delivery Products

16-Nov-2006

Cannasat Therapeutics Inc. and IntelGenx Corp. announced a long-term collaborative agreement to co-develop novel cannabinoid-based products through a combination of Cannasat's and IntelGenx's proprietary drug delivery technologies. The collaboration will focus on the development and production of new formulations of cannabinoid pharmaceutical products, starting with Cannasat's lead product, CAT 310.

"We are excited to work with IntelGenx to develop new cannabinoid pharmaceuticals that could potentially address a wide range of therapeutic indications such as neuropathic pain, where there is currently a large unmet medical need for new therapies. IntelGenx's technology platform complements our existing drug delivery technologies and provides us an opportunity to broaden our growing intellectual property portfolio and product development pipeline. We are committed to expanding our arsenal of drug delivery technologies that can enhance the effectiveness of cannabinoid-based drugs," said David Hill, CEO of Cannasat Therapeutics.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...